Quince Therapeutics, Inc. (IRLA)
NASDAQ: IRLA · Real-Time Price · USD
28.89
-2.84 (-8.97%)
Oct 12, 2026, 12:41 PM EDT - Market open
Quince Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -92.48 | -83.98 | -56.83 | -31.39 | -51.66 | -89.95 |
Depreciation & Amortization | 0.15 | 0.14 | 0.19 | 0.32 | 0.2 | 0.34 |
Loss (Gain) From Sale of Assets | - | - | - | -0.04 | 0.09 | - |
Asset Writedown & Restructuring Costs | 126.81 | - | 17.13 | 5.97 | 0.96 | - |
Loss (Gain) From Sale of Investments | -0.49 | -1.01 | -2.35 | -2.02 | -0.11 | 0.88 |
Stock-Based Compensation | 15.83 | 5.11 | 4.75 | 5.22 | 16.62 | 29.85 |
Other Operating Activities | -99.45 | 25.48 | 5.69 | 1.67 | -0.31 | 0.2 |
Change in Accounts Payable | 6.65 | -0.94 | 0.93 | -0.29 | -5.94 | 1.36 |
Change in Other Net Operating Assets | -3.95 | 13.78 | -1.41 | 2.27 | -3.89 | -5.62 |
Operating Cash Flow | -46.92 | -41.43 | -31.9 | -18.29 | -44.04 | -62.93 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -0.08 | -0.35 | -0.26 | -0.16 | -0.13 | -0.18 |
Sale of Property, Plant & Equipment | - | - | - | 0.09 | 0.07 | - |
Cash Acquisitions | 8 | - | - | -2.12 | 10.59 | - |
Investment in Securities | 18.37 | 23.58 | 22.17 | -2.57 | 7.47 | 59.13 |
Other Investing Activities | - | - | - | -1 | - | - |
Investing Cash Flow | 26.29 | 23.23 | 21.91 | -5.76 | 18 | 58.95 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | - | - | -0.01 | -0.05 | - |
Net Debt Issued (Repaid) | -5.55 | - | - | -0.01 | -0.05 | - |
Issuance of Common Stock | 23.75 | 17.91 | 0.23 | 0.15 | 0.76 | 6.81 |
Other Financing Activities | -0.06 | - | -5 | - | - | - |
Financing Cash Flow | 121.79 | 17.91 | -4.78 | 0.14 | 0.71 | 6.81 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | -2 | -0.11 | 0.23 | 0.08 | 0.18 | 0.06 |
Net Cash Flow | 99.16 | -0.4 | -14.54 | -23.83 | -25.15 | 2.88 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -47 | -41.78 | -32.16 | -18.45 | -44.17 | -63.11 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -26.33 | -166.78 | -148.68 | -99.11 | -263.73 | -424.73 |
Levered Free Cash Flow | -25.75 | -10.61 | -21.13 | -1.94 | -24.18 | -30.54 |
Unlevered Free Cash Flow | -25.75 | -10.61 | -21.13 | -1.94 | -24.18 | -30.54 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.15 | 0.23 | - | - | - | - |
Change in Working Capital | 2.7 | 12.84 | -0.48 | 1.98 | -9.83 | -4.26 |